Merck/Eisai's Keytruda-Lenvima Combo Results in Better Health-Related Quality of Life Measures Compared to Sunitinib

Merck & Co Inc MRK has announced new data from Phase 3 CLEAR (Study 307)/KEYNOTE-581 trial, which evaluated the combinations of Keytruda (pembrolizumab) plus Lenvima from Eisai Co Ltd ESALY, and Lenvima plus everolimus versus Pfizer Inc’s PFE Sutent (sunitinib) in renal cell carcinoma (RCC).
Results from a new analysis evaluating health-related quality of life (HRQoL) based on patient-reported outcomes are being presented during an oral abstract session.
Data were presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.
In an analysis of a secondary endpoint of Health‐Related Quality of Life (HRQoL), scores were assessed.
Keytruda + Lenvima demonstrated similar changes from baseline at mean follow-up (Week 46) on 14 out of 18 HRQoL and disease-related symptom scores and better HRQoL and disease-related symptom scores for various measures including physical functioning, fatigue, dyspnea, and constipation, versus sunitinib.
As reported earlier, the keytruda-lenvima combo showed significant extension in the time patients lived without their disease getting worse in a head-to-head matchup with sunitinib, the standard of care.
Price Action: MRK shares are down 0.43% at $73.79 during the market session on the last check Monday.